We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Has Assertio (ASRT) Outpaced Other Medical Stocks This Year?
Read MoreHide Full Article
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Assertio (ASRT - Free Report) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Assertio is a member of our Medical group, which includes 1181 different companies and currently sits at #9 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Assertio is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for ASRT's full-year earnings has moved 15.2% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
According to our latest data, ASRT has moved about 26.6% on a year-to-date basis. In comparison, Medical companies have returned an average of -17.5%. As we can see, Assertio is performing better than its sector in the calendar year.
One other Medical stock that has outperformed the sector so far this year is Savara Inc. (SVRA - Free Report) . The stock is up 7.3% year-to-date.
For Savara Inc. the consensus EPS estimate for the current year has increased 33.1% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Assertio belongs to the Medical - Drugs industry, which includes 231 individual stocks and currently sits at #146 in the Zacks Industry Rank. Stocks in this group have lost about 28.3% so far this year, so ASRT is performing better this group in terms of year-to-date returns. Savara Inc. is also part of the same industry.
Investors interested in the Medical sector may want to keep a close eye on Assertio and Savara Inc. as they attempt to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Has Assertio (ASRT) Outpaced Other Medical Stocks This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Assertio (ASRT - Free Report) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Assertio is a member of our Medical group, which includes 1181 different companies and currently sits at #9 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Assertio is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for ASRT's full-year earnings has moved 15.2% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
According to our latest data, ASRT has moved about 26.6% on a year-to-date basis. In comparison, Medical companies have returned an average of -17.5%. As we can see, Assertio is performing better than its sector in the calendar year.
One other Medical stock that has outperformed the sector so far this year is Savara Inc. (SVRA - Free Report) . The stock is up 7.3% year-to-date.
For Savara Inc. the consensus EPS estimate for the current year has increased 33.1% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Assertio belongs to the Medical - Drugs industry, which includes 231 individual stocks and currently sits at #146 in the Zacks Industry Rank. Stocks in this group have lost about 28.3% so far this year, so ASRT is performing better this group in terms of year-to-date returns. Savara Inc. is also part of the same industry.
Investors interested in the Medical sector may want to keep a close eye on Assertio and Savara Inc. as they attempt to continue their solid performance.